J.P. Morgan Sticks to Their Hold Rating for Aligos Therapeutics (ALGS)

In a report released today, Eric Joseph from J.P. Morgan maintained a Hold rating on Aligos Therapeutics (ALGSResearch Report), with a price target of $5.00. The company’s shares closed last Wednesday at $1.24, close to its 52-week low of $1.16.

According to, Joseph is a 1-star analyst with an average return of -3.7% and a 44.2% success rate. Joseph covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Karyopharm Therapeutics, and Enanta Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Aligos Therapeutics with a $7.33 average price target, implying a 495.9% upside from current levels. In a report released today, SVB Securities also downgraded the stock to Hold with a $3.00 price target.

See the top stocks recommended by analysts >>

Aligos Therapeutics’ market cap is currently $52.94M and has a P/E ratio of -0.39.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).

Read More on ALGS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More